基于炎症反应探讨升降散防治高血压的机理  

Based on the Inflammatory Response to Explore the Mechanism of Shengjiangsan Prevention and Treatment of Hypertension

作　　者：王英杰 黄于易 刘林[1] 

机构地区：[1]湖北中医药大学中医学院,湖北 武汉

出　　处：《中医学》2023年第8期2252-2256,共5页Traditional Chinese Medicine

摘　　要：高血压是临床常见的心血管综合征,其发病率逐年增高,发病人群呈年轻化趋势,是心脑血管疾病的首要危险因素。升降散为杨栗山创制的温病名方,为瘟疫“十五方之首”,有清解郁热,宣畅气机之功,临床运用该方治疗高血压病疗效显著。炎症假说认为高血压病的发生发展与炎症反应相关,升降散作为治疗温病的名方,其治疗高血压的机理或与其抑制炎症反应相关。据此,本文旨在通过探讨升降散防治高血压的机理,以期推动此方在临床上的广泛运用。Hypertension is a common clinical cardiovascular syndrome. Its incidence is increasing year by year, and the population is getting younger. It is the primary risk factor for cardiovascular and cerebrovascular diseases. Shengjiangsan is a famous prescription for febrile diseases created by Yang Lishan. It is the first of the fifteen prescriptions for plague. It has the function of clearing away stagnated heat and promoting qi movement. The clinical application of this prescription in the treatment of hypertension has a significant effect. The inflammation hypothesis holds that the occurrence and development of hypertension are related to the inflammatory response. As a famous prescription for treating febrile diseases, the mechanism of treating hypertension may be related to its inhibition of inflammatory response. Accordingly, this paper aims to explore the mechanism of Shengjiangsan in the prevention and treatment of hypertension, in order to promote the wide application of this prescription in clinical practice.

关 键 词：炎症反应 升降散 高血压 阳热怫郁 

分 类 号：R54[医药卫生—心血管疾病]